Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Global X Copper Miners ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Inovio Pharmaceuticals Inc — how do they compare? Global X Copper Miners ETF trades at $84.5 (market cap $7.10B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Global X Copper Miners ETF is far larger — about 63.3× Inovio Pharmaceuticals Inc's market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Inovio Pharmaceuticals Inc for 43 Days on average.

COPXINO
Market Cap
$7.10B$112.19M
Volume
2,871,1283,201,278
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$96.45$2.65
52-Week Low
$57.43$0.66
Typical Hold Time
50 Days43 Days
Enterprise Value
—$83.51M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.

The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.

Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COPX
100% Buy0% Sell
Avg holding period · 50 Days
INO
95% Buy5% Sell
Avg holding period · 43 Days

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →